Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Phase 2
36
about 5.6 years
18+
4 sites in FL, MD, OK
What this study is about
This trial is testing if talazoparib, a drug that blocks PARP (a protein involved in DNA repair), can help people with advanced cancer who have changes in their DNA repair genes. The goal is to see if this treatment can stop cancer cells from repairing damaged DNA, leading to cell death. It may also help scientists understand how different PARP inhibitors might work together for some patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Talazoparib
- 2.Undergo Biopsy Procedure
- 3.Undergo Biospecimen Collection
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
talazoparib
oral
Secondary: Overall response rate
biopsy, diagnostic, imaging
Oncology